http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210055922-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbaeaf51c9b24ddf5b214e15c3d394ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_513e23a05c0d76a80040be3207790d9c |
publicationDate | 2021-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20210055922-A |
titleOfInvention | Biomarkers for predicting prognosis after immunotherapy of cancer |
abstract | The present invention relates to a biomarker for selecting a patient for which the occurrence of immune-related adverse events (irAEs) is predicted after treatment with an immunotherapy (PD-1/PD-L1). It is expected that cancer patients, especially thymoma and non-small cell lung cancer patients, can predict the occurrence of irAEs prior to the use of immune anti-cancer drugs, thereby making it possible to determine whether or not to use immuno-anti-cancer drugs for non-small cell lung cancer patients, thereby prolonging life expectancy. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023140713-A1 |
priorityDate | 2019-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 995.